Glucose monitoring
-
Signos and Dexcom Deepen AI Health Tech Partnership
Health tech startup Signos raised $20 million, deepening its partnership with Dexcom and entering the GLP-1 weight loss market. The investment will expand Signos’ AI capabilities for personalized metabolic health guidance, leveraging Dexcom’s glucose monitoring. Their system, FDA-cleared in 2025, offers actionable insights from lifestyle data to promote sustainable healthy habits and weight management, complementing GLP-1 treatments or serving as a standalone program.
